Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab

PURPOSE Detection of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) is strongly associated with recurrence risk in early triple-negative breast cancer (TNBC). Prior studies suggest that ctDNA clearance during neoadjuvant therapy (NAT) may predict pathologic complete response (pCR) and enhance the...

M. Balić, G. Tang, P. Rastogi et al. · 0 citations
Aug 2026

Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer.

PURPOSE Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. EXPERIMENTAL DESIGN 331...

J. Rhoades, Anuj K. Patel, K. Xiong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.